May Health

About May Health

May Health is focused on developing innovative treatments for Polycystic Ovary Syndrome (PCOS). Their mission is to provide a modern approach to PCOS by introducing Ovarian Rebalancing™, a one-time investigational treatment aimed at restoring ovulation through targeted ovarian ablation without the use of hormones.

Products & Services

Ovarian Rebalancing™:An investigational treatment designed to restore ovulation by lowering androgen production through targeted ovarian ablation. It is performed in an outpatient setting and does not require hormones.

Specialties

Polycystic Ovary Syndrome (PCOS) Treatment Ovarian Rebalancing Clinical Trials for Reproductive Health

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 25000000 MR: - FA: $25 million FAN: 25000000	D: 2024-05-13 FD: 2024-05-13	5 investors

Series B Latest

2024-05-13

$25.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Colby Holtshouse

Chief Executive Officer

H

Hugh E. Magen

Chief Technical Officer

R

Rich Ferrick

Vice President, Quality Assurance/Regulatory Affairs

C

Christina Hawley

Vice President, Clinical Affairs

C

Cindy Domecus

Chief Regulatory Advisor

E

Edward Evantash

Chief Medical Advisor

View 24 more team members with Pro

Unlock Full Team Directory

Recent News

May Health Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised